New course on the 505(b)(2) application for marketing approval in the USA
A 505(b)(2) New Drug Application (NDA) is a submission to the Food and Drug Administration (FDA) for approval to market a drug in the USA. It differs from a ‘stand-alone’ NDA in that some of the data on which the applicant relies to demonstrate safety and efficacy have been obtained from publicly available sources rather
New course on the 505(b)(2) application for marketing approval in the USA Read More »